Euvax B consists of highly purified, non-infectious particles of Hepatitis B surface antigen (HBsAg) adsorbed onto aluminum salts as an adjuvant and preserved with thimerosal. It is a recombinant DNA hepatitis B vaccine derived from HBsAg produced by DNA recombinant technology in yeast cells (Saccharomyces cerevisiae).

Euvax B consists of highly purified, non infectious particles of Hepatitis surface antigen (HBsAg) adsorbed onto aluminium salt as an adjuvant and preserved with thimerosal. It is a recombinant DNA hepatitis B vaccine derived from HBsAg produced by DNA recombinant technology in yeast cells (Saccharomyces cerevisiae).

Hepatitis B vaccine is the most effective antibody to the hepatitis B surface antigen (anti-HBs) strategy for preventing the transmission of hepatitis levels B using ELISA. Subjects with anti-HBs titres virus (HBV) in haemodialysis centers.

Euvax-B was clinically identical (not inferior) to the EngerixB reference vaccine, and either vaccine could be used to achieve the World Health Organization goal of immunizing all infants against hepatitis B.

Efficacy of a recombinant hepatitis B vaccine (Euvax-B) in adult patients awaiting liver transplantation: preliminary results Transplant Proc . 1999 Nov;31(7):3055-6. doi: 10.1016/s0041-1345(99)00668-5.

The vaccines included in this study were Heberbiovac-HB (®) (Heber Biotec S.A., Havana, Cuba), Euvax-B (®) (LG Chemical Ltd., Seoul, Korea), Hepavax-Gene (®) (Greencross Vaccine Corp., Seoul, Korea), and Engerix-B (®) (GlaxoSmithKline Biologicals, Rixensart, Belgium).

Patients were given 5 intramuscular injections either preS2/S vaccine (GenHevac B, Pasteur-Merieux) or S vaccine (Recombivax, Merck & Co.) or no treatment as a control.

Conclusion: These surveillance data, obtained under the conditions of universal infant immunization show the novel recombinant HB vaccine, Euvax B™, is safe and well-tolerated with an immunogenicity similar to other recombinant HB vaccines.

Recognizing HBV therapeutics is at the cusp of innovations and breakthroughs, this review summarizes new targets among the HBV viral and host immune systems for which drugs are now in late preclinical development and clinical testing.

HBVaxPro is used to vaccinate against hepatitis B in people who are at risk of exposure to the hepatitis B virus, as determined on the basis of official recommendations. The medicine can only be obtained with a prescription.